Antares Pharma Inc. (ATRS)
-NasdaqCM | Prev Close: | 3.96 |
|---|
| Open: | N/A |
|---|
| Bid: | 3.48 x 200 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 5.25 |
|---|
| Beta: | 0.32 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 2.60 - 5.58 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 935,789 |
|---|
| Market Cap: | 499.65M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.13 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Antares Pharma Welcomes Marvin Samson to Board of DirectorsBusiness Wire(Thu 7:00AM EDT)
- Long-Term Biotech: 3 Names To Discover Nowat Seeking Alpha(Tue, May 21)
- 2013 FDA Drug Approval Calendarat TheStreet(Tue, May 21)
- SmithOnStocks Opines On Stocks: May 19th Editionat Seeking Alpha(Sun, May 19)
- 3 Most Important Upcoming FDA Decisions of 2013at Motley Fool(Fri, May 17)
- Finding Value in the Medical Products and Device Spaces: An Experienced Portfolio Manager Discusses Investing in Overlooked Health Care AreasWall Street Transcript(Fri, May 17)
- Antares: Reiteration Of My Buy Recommendationat Seeking Alpha(Thu, May 16)
- ANTARES PHARMA, INC. FinancialsEDGAR Online Financials(Wed, May 15)
- Contraceptive Ring: Another Under-The-Radar Catalyst For Antaresat Seeking Alpha(Wed, May 15)
- Earnings Volatility Drives These Healthcare Stocks in a New Directionat Wall St. Cheat Sheet(Sun, May 12)
- Antares Pharma to Present at the Bank of America Merrill Lynch 2013 Healthcare ConferenceBusiness Wire(Thu, May 9)
- Antares Pharma Whiffs on Revenuesat Motley Fool(Wed, May 8)
- Antares Pharma Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 8)
- Antares Q1 Results Unimpressive, but Otrexup Could Be Catalystat Motley Fool(Wed, May 8)
- ANTARES PHARMA, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 8)
Comparison
| Symbol | % Chg | Mkt Cap |
|---|
| ATRS | 0.00% | 499.65M |
| BAX | 0.00% | 39.18B |
| COV | 0.00% | 30.70B |
| CSRT.L | 0.96% | 222.23M |
| BDX | 0.00% | 19.43B |
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 24.69 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.12 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.03 |
|---|
| Mean Recommendation*: | 1.3 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Antares Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies, and topical gel-based medicines worldwide.
View More